New York, USA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension, and chronic kidney disease contribute to higher renal cancer rates. The global incidence of renal cancer has also been rising, partly due to improved diagnostic techniques and aging populations.
DelveInsight’s 'Renal Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline renal cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the renal cancer pipeline domain.
Key Takeaways from the Renal Cancer Pipeline Report
- DelveInsight’s renal cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for renal cancer treatment.
- Key renal cancer companies such as Genentech, Allogene Therapeutics, Merck & Co. Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Arcus Biosciences, Infinity Pharmaceuticals, Janux Therapeutics, CRISPR Therapeutics, Arsenal Biosciences, NGM Biopharmaceuticals, Molecure NiKang Therapeutics, Inc., ProfoundBio, RemeGen, and others are evaluating new renal cancer drugs to improve the treatment landscape.
- Promising renal cancer pipeline therapies such as Atezolizumab, ALLO-316, MK-4280A, V940, MK-7684A, MK-6482, Pembrolizumab, 6MW3211, ST-1898, HS-10516, Zanzalintinib, IPI-549, JANX008, CTX130, AB-2100, NGM707, OATD-02, NKT2152, PRO1160, RC198, and others are under different phases of renal cancer clinical trials.
- In July 2024, The US Food and Drug Administration (FDA) granted Fast Track designation to the novel drug ADI-270 for the treatment of patients with metastatic or advanced clear cell renal cell carcinoma (RCC).
- In July 2024, AVEO Oncology announced that the TiNivo-2 Phase III clinical trial in patients with advanced metastatic renal cell carcinoma (RCC) whose tumors had progressed following prior immune checkpoint inhibitor (ICI) treatment did not meet the primary endpoint of increasing progression free survival (PFS) when nivolumab was added to low dose (0.89 mg) FOTIVDA® (tivozanib).
- In June 2024, Adicet Bio announced that the FDA had cleared an investigational new drug (IND) application for ADI-270 to initiate the launch of a Phase I clinical trial of the therapy in patients with relapsed/refractory renal cell carcinoma (RCC).
- In June 2024, Telix Pharmaceuticals announced that the company had completed the submission of a Biologics License Application (BLA) to the FDA to support approval of their radiodiagnostic PET agent, TLX250-CDx for imaging of clear cell renal cell carcinoma (ccRCC).
- In June 2024, the US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Adicet Bio, allowing the company to begin a Phase I clinical trial of ADI-270 for relapsed or refractory renal cell carcinoma (r/r RCC).
- In May 2024, Arsenal Biosciences dosed the first subject in a Phase I/II clinical trial of AB-2100, a new therapy for treating patients with clear-cell renal cell carcinoma (ccRCC).
- In April 2024, Telix announced that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix), PET/CT imaging in patients with clear cell renal cell carcinoma (ccRCC).
Request a sample and discover the recent advances in renal cancer treatment drugs @ Renal Cancer Pipeline Report
The renal cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage renal cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the renal cancer clinical trial landscape.
Renal Cancer Overview
Renal cancer, also known as kidney cancer, originates in the kidneys, which are vital organs responsible for filtering waste products from the blood and producing urine. The most common type of renal cancer is renal cell carcinoma (RCC), which begins in the lining of the small tubes within the kidney. Although the exact cause of renal cancer is not fully understood, several risk factors have been identified, including smoking, obesity, high blood pressure, and certain genetic conditions. Early detection is crucial as the disease often presents with symptoms only in advanced stages. Symptoms may include blood in the urine, persistent back pain, and unexplained weight loss.
Treatment options for renal cancer vary depending on the stage and grade of the tumor, as well as the patient's overall health. Early-stage renal cancer is often treated with surgical removal of the affected kidney or tumor, which can be done via open surgery or minimally invasive laparoscopic techniques. For more advanced stages, treatment may involve a combination of surgery, targeted therapy, immunotherapy, and radiation therapy. Advances in medical research have led to the development of newer therapies that target specific molecular pathways involved in cancer growth, offering hope for improved outcomes and survival rates for patients.
Find out more about renal cancer treatment drugs @ Drugs for Renal Cancer Treatment
A snapshot of the Renal Cancer Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Atezolizumab | Genentech | Phase III | Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors | Intravenous |
| 6MW3211 | Mabwell (Shanghai) Bioscience Co., Ltd., | Phase II | Programmed cell death-1 ligand-1 inhibitors | Intravenous |
| NKT 2152 | NiKang Therapeutics | Phase II | Endothelial PAS domain-containing protein 1 inhibitors | Oral |
| PRO1160 | ProfoundBio US Co. | Phase I/II | Undefined mechanism | Intravenous |
| ALLO-316 | Allogene Therapeutics | Phase I | Immunologic cytotoxicity; T lymphocyte replacements | Parenteral |
Learn more about the emerging renal cancer pipeline therapies @ Renal Cancer Clinical Trials
Renal Cancer Therapeutics Assessment
The renal cancer pipeline report proffers an integral view of the renal cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Renal Cancer Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Cytotoxic T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Poly(ADP-ribose) polymerase inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Immunostimulants, Endothelial PAS domain-containing protein 1 inhibitors
- Key Renal Cancer Companies: Genentech, Allogene Therapeutics, Merck & Co. Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Arcus Biosciences, Infinity Pharmaceuticals, Janux Therapeutics, CRISPR Therapeutics, Arsenal Biosciences, NGM Biopharmaceuticals, Molecure NiKang Therapeutics, Inc., ProfoundBio, RemeGen and others.
- Key Renal Cancer Pipeline Therapies: Atezolizumab, ALLO-316, MK-4280A, V940, MK-7684A, MK-6482, Pembrolizumab, 6MW3211, ST-1898, HS-10516, Zanzalintinib, IPI-549, JANX008, CTX130, AB-2100, NGM707, OATD-02, NKT2152, PRO1160, RC198 and others.
Dive deep into rich insights for new drugs for renal cancer treatment, visit @ Renal Cancer Drugs
Table of Contents
| 1. | Renal Cancer Pipeline Report Introduction |
| 2. | Renal Cancer Pipeline Report Executive Summary |
| 3. | Renal Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Renal Cancer Clinical Trial Therapeutics |
| 6. | Renal Cancer Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Renal Cancer Pipeline: Late-Stage Products (Phase III) |
| 8. | Renal Cancer Pipeline: Mid-Stage Products (Phase II) |
| 9. | Renal Cancer Pipeline: Early-Stage Products (Phase I) |
| 10. | Renal Cancer Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Renal Cancer Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Renal Cancer Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the renal cancer pipeline therapeutics, reach out @ Renal Cancer Treatment Drugs
Related Reports
Renal Cell Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key renal cell carcinoma companies, including AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, among others.
Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key renal cell carcinoma companies, including AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, among others.
Advanced Renal Cell Carcinoma Pipeline
Advanced Renal Cell Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key advanced renal cell carcinoma companies, including Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, among others.
Advanced Renal Cell Carcinoma Market
Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key advanced renal cell carcinoma companies, including Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, among others.
Metastatic Renal Cell Carcinoma Pipeline
Metastatic Renal Cell Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key metastatic renal cell carcinoma companies, including AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., among others.
Oncology Conference Coverage Services
DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies.
Other Business Consulting Services
Healthcare Competitive Intelligence
Healthcare Portfolio Management
Case Study
Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
